About ImCheck Therapeutics
ImCheck Therapeutics is a company based in Marseille (France) founded in 2015 was acquired by Ipsen in December 2025. It operates as a HealthTech. ImCheck Therapeutics has raised $185.07 million across 6 funding rounds from investors including Pfizer, ARE and EQT. ImCheck Therapeutics offers products and services including ICT01 and ICT41. ImCheck Therapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Marseille, France
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ImCheck Therapeutics
ImCheck Therapeutics offers a comprehensive portfolio of products and services, including ICT01 and ICT41. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
ICT01 is developed for treating Acute Myeloid Leukemia.
ICT41 is designed for immune system modulation therapy.
Unlock access to complete
Funding Insights of ImCheck Therapeutics
ImCheck Therapeutics has successfully raised a total of $185.07M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $22.4 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Grant — $22.4M
-
First Round
First Round
(02 May 2017)
- Investors Count 18
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2024 | Amount | Grant - ImCheck Therapeutics | Valuation |
investors |
|
| Jun, 2022 | Amount | Series C - ImCheck Therapeutics | Valuation | Earlybird , Andera Partners | |
| Sep, 2020 | Amount | Series B - ImCheck Therapeutics | Valuation | Pureos Bioventures |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ImCheck Therapeutics
ImCheck Therapeutics has secured backing from 19 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, ARE and EQT. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Earlybird is recognized as a venture capital investor focused on early-stage tech companies.
|
Founded Year | Domain | Location | |
|
Capital is provided to firms for growth, buyouts, and acquisitions.
|
Founded Year | Domain | Location | |
|
Biotech startups are funded through venture capital in life sciences.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ImCheck Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - ImCheck Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Imcheck Therapeutics Comparisons
Competitors of ImCheck Therapeutics
ImCheck Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Imcheck Therapeutics
Frequently Asked Questions about ImCheck Therapeutics
When was ImCheck Therapeutics founded?
ImCheck Therapeutics was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Where is ImCheck Therapeutics located?
ImCheck Therapeutics is headquartered in Marseille, France. It is registered at Marseille, Provence-alpes-cote D'azur, France.
Is ImCheck Therapeutics a funded company?
ImCheck Therapeutics is a funded company, having raised a total of $185.07M across 6 funding rounds to date. The company's 1st funding round was a Series B of $7.1M, raised on May 02, 2017.
What does ImCheck Therapeutics do?
ImCheck Therapeutics is engaged in developing next-generation immunotherapeutic antibodies. The company specializes in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. Solutions are targeted for the treatment of cancer, infectious diseases, and autoimmune conditions. Research and development efforts are centered on leveraging unique expertise in immunomodulation to address unmet medical needs across various therapeutic areas.
Who are the top competitors of ImCheck Therapeutics?
ImCheck Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does ImCheck Therapeutics offer?
ImCheck Therapeutics offers ICT01 and ICT41.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.